{
  "meta": {
    "id": "test10",
    "title": "Anticancer_Drugs-Targeted_Therapy_and_Monoclonal_Antibodies",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A 45 y/o male presents with fatigue, unintentional weight loss, and left upper quadrant abdominal discomfort. Physical examination shows splenomegaly. Lab tests show leukocytosis. The peripheral blood smear shows increased basophils, myelocytes, and segmented neutrophils. Bone marrow biopsy confirms hypercellularity with increased myeloid precursors and the presence of the Philadelphia chromosome (BCR-ABL fusion gene). Which of the following drugs would be your DOC to treat the patient?",
      "options": [
        {
          "label": "A",
          "text": "Ponatinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Imatinib",
          "correct": true
        },
        {
          "label": "C",
          "text": "Nilotinib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dasatinib",
          "correct": false
        }
      ],
      "correct_answer": "B. Imatinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:498px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Generation</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drugs</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>1st Generation</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Erlotinib</li>\n<li>Gefitinib</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>2nd Generation</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Afatinib</li>\n<li>Dacomitinib</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>3rd Generation</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Osimertinib</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>4th Generation</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Mobocertinib</li>\n</ul>\n</td>\n</tr>\n</tbody>\n\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "db416545"
    },
    {
      "text": "A 60-year-old female patient diagnosed with a gastrointestinal stromal tumor (GIST) has been started on first-line treatment. Genetic testing reveals a mutation in the c-KIT gene. After several months, the patient develops resistance to the initial therapy. The oncologist considers alternative medications. Which of the following drugs is specifically known for selectively inhibiting the Platelet-Derived Growth Factor Receptor (PDGFR) rather than multiple tyrosine kinase receptors?",
      "options": [
        {
          "label": "A",
          "text": "Imatinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sunitinib",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ripretinib",
          "correct": true
        },
        {
          "label": "D",
          "text": "Regorafenib",
          "correct": false
        }
      ],
      "correct_answer": "C. Ripretinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Primary Targets</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Line of Therapy in GIST</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Imatinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>c-KIT, PDGFR\u03b1</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>First-line</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Sunitinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Multiple TKs: KIT, PDGFR, VEGFR</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Second-line</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Regorafenib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Multikinase: KIT, PDGFR, VEGFR, RAF, etc.</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Third-line</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Ripretinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Broad-spectrum KIT and PDGFR\u03b1 <span class=\"customMeta\" data-dictid=\"f03ca2d2a716927771901227bc175a\">inhibition</span> (switch-control)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Fourth-line or resistant cases</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "7707e57e"
    },
    {
      "text": "Which of the following conditions is not commonly treated with Bruton\u2019s Tyrosine Kinase (BTK) inhibitors?",
      "options": [
        {
          "label": "A",
          "text": "Mantle Cell Lymphoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Marginal Zone Lymphoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chronic Lymphocytic Leukemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hodgkin's Lymphoma",
          "correct": true
        }
      ],
      "correct_answer": "D. Hodgkin's Lymphoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Condition</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>BTK <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">Inhibitor</span> Use</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Comments</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Mantle Cell Lymphoma</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Yes</strong> (e.g., Ibrutinib)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Approved indication</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Marginal Zone Lymphoma</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Yes</strong> (e.g., Zanubrutinib)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Used especially in relapsed/refractory settings</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Chronic Lymphocytic Leukemia</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Yes</strong> (Ibrutinib, Acalabrutinib)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>First-line and relapsed settings</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Hodgkin's Lymphoma</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>No</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Not a BTK-driven disease; treated with chemotherapy/immunotherapy</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "903f8d49"
    },
    {
      "text": "Match the following drugs to their appropriate mutation targets in cancer treatment: 1. Erlotinib A. HER2 (+)ve Breast Cancer 2. Osimertinib B. HER1 (EGFR) mutation in Non-Small Cell Lung Cancer 3. Lapatinib C. T790M mutation in EGFR receptor 4. Neratinib D. Trastuzumab resistant HER2 (+)ve Breast Cancer",
      "options": [
        {
          "label": "A",
          "text": "1-C, 2-B, 3-D, 4-A",
          "correct": false
        },
        {
          "label": "B",
          "text": "1-B, 2-C, 3-A, 4-D",
          "correct": false
        },
        {
          "label": "C",
          "text": "1-C, 2-B, 3-A, 4-D",
          "correct": false
        },
        {
          "label": "D",
          "text": "1-B, 2-C, 3-D, 4-A",
          "correct": true
        }
      ],
      "correct_answer": "D. 1-B, 2-C, 3-D, 4-A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Matched Target</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Mechanism & Clinical Use</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Erlotinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>B. HER1 (EGFR) <span class=\"customMeta\" data-dictid=\"7a67bdf6f81692777193cfd480f228\">mutation</span> in NSCLC</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Reversible tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> (TKI) of <strong>EGFR (HER1)</strong>; used in <strong>EGFR-mutant NSCLC</strong>.</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Osimertinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>C. T790M EGFR mutation</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>3rd-generation <span class=\"customMeta\" data-dictid=\"ee77d507701692777190bfcf47b497\">irreversible</span> EGFR-TKI that targets <strong>T790M</strong>, a common resistance mutation.</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Lapatinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>A. HER2 (+)ve Breast Cancer</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Dual <strong>HER2 and EGFR</strong> TKI used for <strong>HER2-positive breast cancer</strong>, usually after trastuzumab.</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Neratinib</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>D. Trastuzumab-resistant HER2+ Cancer</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Irreversible pan-HER <span class=\"customMeta\" data-dictid=\"b5fb56a28b1692777190396ae8b625\">inhibitor</span> <span class=\"customMeta\" data-dictid=\"e4865847fa169277720044d7b530b0\">targeting</span> <strong>HER1, HER2, and HER4</strong>, effective after <span class=\"customMeta\" data-dictid=\"3c1f84a831169277720091463322a7\">trastuzumab</span> failure.</p>\n</td>\n</tr>\n</tbody>\n</table>\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Target</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Common Mutation/Context</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Targeted Drugs</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>EGFR (HER1)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>NSCLC with EGFR mutations</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Erlotinib, Gefitinib, Afatinib</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>T790M mutation</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Resistance <span class=\"customMeta\" data-dictid=\"7a67bdf6f81692777193cfd480f228\">mutation</span> in EGFR+ NSCLC</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Osimertinib</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>HER2</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>HER2-positive breast cancer</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Trastuzumab, Pertuzumab, Lapatinib, Neratinib</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Trastuzumab-resistance</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>HER2+ breast cancer non-responsive to trastuzumab</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Neratinib, Tucatinib</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "https://image.prepladder.com/content/luCUITBGFj6QRRmxOs2S1746256860.mp3",
      "video": "",
      "uid": "4acacc37"
    },
    {
      "text": "Match the drugs & their clinical use: Drug Clinical Use 1. Pazopanib A. Cholangiocarcinoma 2. Midostaurin B. Urothelial Carcinoma 3. Erdafitinib C. Acute Myeloid Leukemia (AML) with FLT-3 mutation 4. Infigratinib D. Renal Cell Carcinoma (RCC)",
      "options": [
        {
          "label": "A",
          "text": "1-D, 2-C, 3-B, 4-A",
          "correct": true
        },
        {
          "label": "B",
          "text": "1-D, 2-C, 3-A, 4-B",
          "correct": false
        },
        {
          "label": "C",
          "text": "1-C, 2-D, 3-A, 4-B",
          "correct": false
        },
        {
          "label": "D",
          "text": "1-C, 2-D, 3-B, 4-A",
          "correct": false
        }
      ],
      "correct_answer": "A. 1-D, 2-C, 3-B, 4-A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"width:624px\">\n<tbody>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p><strong>Drug Name</strong></p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p><strong>Clinical Use</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Pazopanib, Axitinib, Tivozanib</p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Sorafenib, Lenvatinib</p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC), <span class=\"customMeta\" data-dictid=\"6165f47a8c1692777188c0dfc0d75d\">Hepatocellular</span> <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (HCC)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Sunitinib, Regorafenib</p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Renal Cell <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> (RCC), <span class=\"customMeta\" data-dictid=\"b3a647ce2516927771881427f56c1d\">Gastrointestinal</span> Stromal Tumors (GIST)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Vandetanib, Cabozantinib</p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Medullary <span class=\"customMeta\" data-dictid=\"988c19e3131692777183b6744d1920\">Carcinoma</span> of the Thyroid</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Midostaurin, Gilteritinib</p>\n</td>\n<td style=\"border-color:#000000; border-style:solid\">\n<p>Acute <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">Myeloid</span> <span class=\"customMeta\" data-dictid=\"4521dbf4b91692777191a73002bf98\">Leukemia</span> (AML) with FLT-3 mutation</p>\n</td>\n</tr>\n</tbody>\n</table>\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug Name</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Clinical Use</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Erdafitinib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Urothelial Carcinoma</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Pemigatinib, Infigratinib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Cholangiocarcinoma</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "50d16058"
    },
    {
      "text": "A 58-year-old male patient diagnosed with malignant melanoma has not responded to initial therapies. His oncologist is considering targeted therapy options. Which of the following inhibitors can be used in malignant melanoma?",
      "options": [
        {
          "label": "A",
          "text": "Sirolimus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Binimetinib",
          "correct": true
        },
        {
          "label": "C",
          "text": "Idelalisib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adagrasib",
          "correct": false
        }
      ],
      "correct_answer": "B. Binimetinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:625px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>Inhibitor Type</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>Drugs</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>Uses</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>RAS Inhibitors</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>Sotorasib, <strong>Adagrasib</strong> <strong>(Option D Ruled out)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>NSCLC with KRAS mutation</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>B-RAF Inhibitors</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>Vemurafenib, Dabrafenib, Encorafenib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>Malignant <span class=\"customMeta\" data-dictid=\"e42297345d16927771922d2d0dc020\">Melanoma</span> with B-RAF mutation</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>MEK Inhibitors</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>Trametinib, Cobimetinib, <strong>Binimetinib (Option B)</strong>, Selumetinib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>Malignant Melanoma</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>PI3K Inhibitors</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>Idelalisib</strong> <strong>(Option C\u00a0Ruled out)</strong>, Copanlisib, Duvelisib, Umbralisib, Alpelisib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>B Cell <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">Lymphoma</span> (CLL, SLL, FL)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>mTOR Inhibitors</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p><strong>Sirolimus (Option A Ruled out)</strong>, Temsirolimus, Everolimus</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:bottom\">\n<p>RCC (Renal Cell Carcinoma), Breast Cancer, <span class=\"customMeta\" data-dictid=\"cde2dcfb251692777195bb7a41d550\">PNET</span> (Pancreatic <span class=\"customMeta\" data-dictid=\"7eca2476201692777193e0a0959bd7\">Neuroendocrine</span> Tumors)</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "68b2bedc"
    },
    {
      "text": "A 52-year-old female presents with a diagnosis of invasive ductal carcinoma of the breast. The tumour measures 3 cm in diameter and has been staged as T2N1M0. Immunohistochemical testing reveals that the cancer cells overexpress the HER2 protein and are ER-negative. The patient has no significant comorbidities and has been scheduled for surgery. Which of the following drugs is most suitable for this patient as part of her adjuvant chemotherapy regimen",
      "options": [
        {
          "label": "A",
          "text": "Tamoxifen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cetuximab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trastuzumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Bevacizumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Trastuzumab",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/KI5ffGfpZT4iiU50IllV1736435764.png"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "9fc46123"
    },
    {
      "text": "A 60-year-old male with a significant smoking history presents with a persistent cough, dyspnea, weight loss, and fatigue. A Chest CT reveals a suspicious mass in the right upper lobe. A biopsy of the mass shows adenocarcinoma. Further molecular testing reveals high PD-L1 expression (>50%) and no actionable mutations in EGFR, ALK, or ROS1. Which of the following drugs would you choose as the first line of treatment in this case?",
      "options": [
        {
          "label": "A",
          "text": "Erlotinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bevacizumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pembrolizumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ipilimumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Pembrolizumab",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/lWKK6hhPg6yCL2JANa4U1736435838.png",
        "https://image.prepladder.com/content/T9qsYnDojI7vWUDTbesP1736435889.png"
      ],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:NaN\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align: center;\"><strong>Blocks CTLA4 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> </strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align: center;\"><strong>Blocks PD-L-1 <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> </strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align: center;\"><strong>Blocks PD-1 receptor</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Ipilimumab</li>\n<li>Tremelimumab</li>\n</ul>\n<br/>\n\t\t\t\u00a0</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Atezolizumab</li>\n<li>Avelumab</li>\n<li>Durvalumab</li>\n</ul>\n<br/>\n\t\t\t\u00a0</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Nivolumab</li>\n<li>Cepilimumab</li>\n<li>Pembrolizumab</li>\n</ul>\n<p>\u00a0</p>\n<p>\u00a0</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "c3582345"
    },
    {
      "text": "A 45-year-old man presents to the dermatology clinic with chronic, thick, silvery-white, scaly plaques on his elbows, knees, and lower back. He reports that the plaques have been present for several years and have gradually worsened. He has tried various OTC creams with minimal relief. The plaques are extensive on examination, and the patient rates his itching and discomfort as moderate to severe. Which of the following drugs is NOT relevant for this patient\u2019s treatment?",
      "options": [
        {
          "label": "A",
          "text": "Ixekizumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Secukinumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Etanercept",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mogamulizumab",
          "correct": true
        }
      ],
      "correct_answer": "D. Mogamulizumab",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/UxLbMXCiokQFduwWthCp1736435945.png"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "ca653abf"
    },
    {
      "text": "A 65-year-old male with hypertension and CKD presents with gross hematuria and flank pain. Imaging studies reveal a 7 cm mass in the left kidney concerning renal cell carcinoma. He undergoes a radical nephrectomy with pathological confirmation of clear cell RCC, pT3aN0M0 (stage III). Due to his advanced stage, you are considering adjuvant therapy with Aldesleukin. Which of the following is a potential mechanism of action of aldesleukin in treating RCC?",
      "options": [
        {
          "label": "A",
          "text": "Induction of angiogenesis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Activation of T cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Inhibition of vascular endothelial growth factor (VEGF)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Direct cytotoxicity against tumor cells",
          "correct": false
        }
      ],
      "correct_answer": "B. Activation of T cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "cdf0e807"
    },
    {
      "text": "A 65-year-old male with refractory multiple myeloma has undergone multiple lines of treatment including proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation. Despite these treatments, his disease has progressed. His oncologist decided to start him on a novel therapy that targets B-cell maturation antigen (BCMA) and delivers a cytotoxic agent to myeloma cells. Which drug is the patient likely being prescribed?",
      "options": [
        {
          "label": "A",
          "text": "Daratumumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Elotuzumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Belantamab Vedotin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ixekizumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Belantamab Vedotin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Target</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Approved for</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Gemtuzumab Ozogamicin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 CD33 + Calicheamicin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Relapsed AML</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Brentuximab Vedontin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 CD30 + Vedontin</p>\n<p>(microtubule cleaver)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 Hodgkin's <span class=\"customMeta\" data-dictid=\"5a31d184f21692777191a2e457d646\">lymphoma</span> (refractory)</p>\n<p>\u00b7 Large B-cell lymphoma</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Belantamab Vedontin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 BCMA+ Vedontin</p>\n<p>(microtubule cleaver)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 <span class=\"customMeta\" data-dictid=\"3790c638ab16927771970a0a41d3ab\">Refractory</span> multiple myeloma</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Polatuzumab Vedontin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 CD19 + Vedontin</p>\n<p>(microtubule cleaver)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 Relapsed AML</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Moxetumomab Pasudotox</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 CD22 + <span class=\"customMeta\" data-dictid=\"8d0fca798b1692777191b6cd41880f\">Linked</span> to <span class=\"customMeta\" data-dictid=\"dea08f9dd81692777196a5f62e6862\">pseudomonas</span> <span class=\"customMeta\" data-dictid=\"41329dc9381692777200a9b6d57cf4\">toxin</span> A</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00b7 <span class=\"customMeta\" data-dictid=\"a4789768d21692777188e77f1969cd\">Hairy</span> cell leukemia</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "da7ffd01"
    },
    {
      "text": "A 58-year-old female with metastatic melanoma has experienced disease progression after treatment with a BRAF inhibitor and an immune checkpoint inhibitor targeting CTLA-4. Her oncologist now recommends a monoclonal antibody Pembrolizumab, that targets the PD-1 receptor to help reinvigorate T-cell activity against the tumor. Pembrolizumab can be used in the treatment of all of the following, except?",
      "options": [
        {
          "label": "A",
          "text": "Non-small cell lung cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Breast cancer",
          "correct": false
        },
        {
          "label": "C",
          "text": "Renal Cell carcinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Multiple myeloma",
          "correct": true
        }
      ],
      "correct_answer": "D. Multiple myeloma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "0f6b073b"
    },
    {
      "text": "A 48-year-old woman with newly diagnosed HER2-positive invasive ductal carcinoma is started on a neoadjuvant therapy that includes a monoclonal antibody. This antibody specifically binds to the extracellular domain of the HER2 receptor, blocking the activation of downstream signaling pathways involved in cell growth and survival. Additionally, it enhances antibody-dependent cellular cytotoxicity (ADCC), leading to improved immune-mediated destruction of tumor cells. Despite the initial efficacy of the treatment, her oncologist monitors her closely for potential cardiotoxicity, a known side effect of this therapy. Which monoclonal antibody is the patient most likely receiving?",
      "options": [
        {
          "label": "A",
          "text": "Pertuzumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Trastuzumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cetuximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bevacizumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Trastuzumab",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/VvBJg36GLVy5qZ4ihGbw1736436022.png"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "95a320cd"
    }
  ]
}